Replies to post #2792 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA’s pro forma net cash @12/31/23=$176.3M—treating ENTA’s deferred-royalty obligations as debt (as is done under GAAP [#msg-172603887]—but see note at bottom of this post). The $176.3M figure, which is down $24.3M relative to 9/30/23, consists of:

• $327.9M net current assets on the 12/31/22 balance sheet (https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001177648/000095017024012796/enta-20231231.htm#consolidated_balance_sheets );

• ($151.6M) deferred long-term liabilities on the 12/31/23 balance sheet relating to the OMERS royalty agreement. ($36.5M of liabilities relating to the OMERS agreement are booked as current liabilities and hence are included in the $327.9M figure in the first bulleted item.)

Note: Excluding the “debt” associated with the OMERS royalty agreement, ENTA’s pro forma net cash at 12/31/23 was $364.1M ($176.3M + $151.6M + $36.5M).